Findings promising for Advanced Viral skin-healing formula
-
- June
- 18
Advanced Viral Research Corp., a biopharmaceutical company based in Yonkers, today announced positive preliminary results from its Phase II dermotological study of a topical drug called AVR118. Early findings show that treatment with AVR118 appears to reduce inflammation and redness associated with surgical incisions and dermabrasion, the company said.
The first group of patients underwent dermabrasion for severe acne and then had the topical applied to half of their inflamed facial tissue. The treated area showed less inflammation and a reduction of redness and swelling of acne lesions. The second group had the drug applied to one of two incisions following plastic surgery. One of two patients had a decrease in inflammation on the treated side.
“I am very encouraged by this data,� Stephen M. Elliston, President and Chief Executive Officer of Advanced Viral, said in a written statement. “The response we’ve seen thus far indicates that AVR118 may have beneficial activity in both sets of patients. A preliminary and unexpected result was the reduction of the inflammatory symptoms of acne. We plan to amend the protocol to include patients being treated solely for acne, given the potential of this market.�
This entry was posted
on Monday, June 18th, 2007 at 4:10 pm by Alison Bert.
You can follow any responses to this entry through the RSS 2.0 feed.
Share and Enjoy: 
| 
Print
| 
Email
